Trade Mark Journal No.2025/022 30 May 2025

WO0000001854541 (5,10)

Office of origin: European Union Intellectual Property Office (EUIPO)

Date of International Registration:21 March 2025
Date of designation in the UK: 21 March 2025
Image for mark 1854541_TIF XERVYTEG

International priority date claimed: 10 October 2024 (European Union Intellectual Property Office (EUIPO)) (019089874)
Class 5
Pharmaceutical and biopharmaceutical products and preparations for the medical treatment of gastrointestinal diseases and disorders emanating from microbiota dysfunction; pharmaceutical and biopharmaceutical products and preparations used for the treatment of cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases; pharmaceuticals used to maintain health or restore health to a human subject in the field of treatment of a disturbed microbial community, namely, for the treatment of dysbiosis, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases; biological preparations in the nature of microorganisms used to maintain health or restore health to a human subject in the field of treatment of a disturbed microbial community, namely, for the treatment of dysbiosis, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases.
Class 10
Medical and surgical apparatus and instruments; drug delivery devices, including medical apparatus and instruments for administration of pharmaceutical and biopharmaceutical products and preparations; drug delivery devices to treat gut microbiome-related disorders, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases; drug delivery devices to treat gut microbiome-related disorders, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, in the nature of a kit comprising a prefilled suspension bag and administration tube set.

MAAT PHARMA

Representative: SANTARELLI (Société IPSIDE), Tour TRINITY 1 Bis, Place de la Défense, F-92400 Courbevoie, FRANCE